What You Should Know:
– Ryght AI, a provider of real-time generative AI healthcare technology for clinical research, today announced that the prestigious Winship Cancer Institute of Emory University has joined its unique Ryght Research Network.
– The global network creates an AI digital twin of every research site worldwide, allowing distinguished academic institutions like Winship to leverage Ryght’s AI platform and applications to revolutionize clinical trial processes and streamline workflows.
Streamlining Clinical Trial Processes
The Ryght Research Network utilizes advanced generative AI capabilities to process site-specific and industry-wide data. This delivers real-time insights that enable sponsors and Contract Research Organizations (CROs) to identify the best sites for their trials, while empowering sites to make data-driven decisions that run the very best studies for their patients. The network automates crucial tasks such as site selection, feasibility assessment, automated study budgeting, and patient referrals. This transforms traditional trial workflows into automated communication between sponsors and sites, simplifying trial management and accelerating patient selection for all parties.
With over 400 active clinical trials, Winship physicians, researchers, and staff are positioned to not only bring on more studies but, more importantly, ensure these trials enroll on time, thereby maximizing operational efficiency and scale.
“We are thrilled to join the Ryght Research Network bringing state-of-the-art AI solutions to our patients and staff,” said Suresh Ramalingam, MD, FACP, FASCO, Executive Director of Winship Cancer Institute. “Our commitment to excellence in cancer research aligns perfectly with the goals of Ryght AI as we streamline our processes, accelerate access to potentially life-saving therapies, and bring the right studies to our patients in a timely manner.”
